Proteomic Markers of Alcohol Abuse (Phase 1)

酒精滥用的蛋白质组标记（第一阶段）

• 批准号: 6807070
• 负责人: LAWRENCE DOUGLAS SNELL
• 金额: $ 19.81万
• 依托单位: LOHOCLA RESEARCH CORPORATION
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-30 至 2005-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6807070
• 关键词: alcoholic beverage consumption; alcoholism /alcohol abuse; amine oxidase (flavin); biomarker; biotechnology; blood chemistry; clinical research; computer program /software; diagnosis quality /standard; enzyme activity; enzyme linked immunosorbent assay; high performance liquid chromatography; human data; mass spectrometry; measurement; method development; protein glutamine gamma glutamyltransferase; protein quantitation /detection; protein structure; proteomics; serology /serodiagnosis

DESCRIPTION (provided by applicant): Alcohol dependence and hazardous levels of ethanol ingestion are under-diagnosed and under-reported. Significant effort has been expended to develop biological markers (diagnostics) for monitoring levels and/or recency of alcohol use (state markers) and markers for predisposition to alcohol dependence (trait, "etiologic", markers). However, this area of research has not yet generated unequivocal tools to be used by treatment and prevention specialists and others interested in such information. A new era in science emerged with the detailed knowledge of the human genome and the human proteome is now being defined. The power of proteomic techniques and informatics technology is ready to be applied to the search for better (more reliable) diagnostic tools for hazardous alcohol use and alcoholism. Lohocla Research Corporation has access to biological samples (plasma, serum and platelets) from over 1,000 individuals who are well characterized with regards to drinking habits, medical/psychiatric disorders, family history of medical/psychiatric disorders, drug use, etc. Lohocla will partner with Eprogen, the developers of the ProteoSep TM proteomic technology, to discover and test a novel panel of diagnostics for alcohol use, abuse and alcoholism. Phase I studies, will test the feasibility of using ProteoSep TM technology to identify and quantitate proteins already known to be altered by alcohol intake/alcoholism and to identify novel candidate markers. We will establish proteomic methodology (ProteoSep TM) to accurately measure currently used state markers for excessive alcohol ingestion (GGT, AST and CDT) in plasma and serum samples and develop a measurement, with ProteoSep TM technology, of MAO-B protein in platelet samples. A panel of bioinformatic/statistical tools will be applied to search for new markers. If we are able to successfully measure the levels of proteins such as GGT, AST, CDT and MAO, these proteins will form "internal standards" against which other novel marker proteins can be tested in Phase II. Phase I studies will also provide the initial panel of candidate markers to be assessed in a significantly greater number of subjects in Phase ll.

描述（由申请人提供）：酒精依赖和酒精摄入的危险水平被诊断和报告不足。已经花费了大量的努力来开发用于监测酒精使用的水平和/或新近度（状态标记）的生物标记（诊断）和用于酒精依赖倾向的标记（性状，“病因学”标记）。然而，这一领域的研究尚未产生明确的工具，供治疗和预防专家以及对这类信息感兴趣的其他人使用。 随着对人类基因组和人类蛋白质组的详细了解，一个新的科学时代出现了。蛋白质组学技术和信息学技术的力量已经准备好应用于寻找更好（更可靠）的诊断工具，用于危险的酒精使用和酒精中毒。洛霍克拉研究公司可以获得生物样本Lohocla将与ProteoSep TM蛋白质组学技术的开发商Eprogen合作，发现和测试一种新的酒精使用诊断方法，滥用和酗酒。 第一阶段研究将测试使用ProteoSep TM技术识别和定量已知因酒精摄入/酒精中毒而改变的蛋白质的可行性，并识别新的候选标记物。我们将建立蛋白质组学方法（ProteoSep TM），以准确测量血浆和血清样本中目前使用的过量酒精摄入状态标志物（GGT，AST和CDT），并开发一种测量方法，使用ProteoSep TM技术，测量血小板样本中的MAO-B蛋白。一组生物信息学/统计学工具将用于搜索新的标记物。 如果我们能够成功地测量GGT、AST、CDT和MAO等蛋白质的水平，这些蛋白质将形成“内部标准”，可以在II期中测试其他新的标志物蛋白质。I期研究还将提供候选标志物的初始组，以在II期中在显著更多数量的受试者中进行评估。